Dalton Pharma and Boehringer Ingelheim Announce the Renewal of Chemistry Services Agreement
News Feb 24, 2009
Dalton Pharma Services announces the renewal of its Chemistry Services Agreement with Boehringer Ingelheim (Canada) Ltd.
Under the agreement Dalton will continue to provide chemistry services in support of Boehringer’s pharmaceutical development programs.
Peter Pekos, President of Dalton Pharma Services, said: “We are extremely pleased to continue our relationship with Boehringer Ingelheim (Canada) Ltd. The renewal of our chemistry services agreement demonstrates Boehringer Ingelheim’s deep commitment to research in Canada. We look forward to another successful collaboration with this world class organization.”
Tuberculosis (TB), an ancient and notoriously difficult disease to treat, has killed millions through the course of human history; and the antibiotics that have been used to fight the disease in recent history are becoming less and less effective. In the face of this reality, researcher Prof. Dennis Wright has improved upon a new way to thwart the tricky pathogen, mycobacterium tuberculosis.READ MORE
Researchers have solved the structures of the cancer-promoting enzymes USP25 and USP28, and identified significant differences in their activities. This knowledge provides the molecular basis for the development of new and highly specific anti-cancer drugs, with a low risk of side-effects.READ MORE